Diabetes Drug's heart benefits probed in tiny, terminated study

NCT ID NCT05139914

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see how dapagliflozin, a diabetes drug, affects blood vessel health in people with type 2 diabetes. Researchers planned to measure blood pressure and other markers of vascular function. However, the trial was terminated early and only enrolled 4 participants, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dapagliflozin

What this could lead to

If successful, this could help explain how dapagliflozin protects the heart and blood vessels in people with type 2 diabetes.

What could go wrong

The trial was terminated early with only 4 participants, so results are very limited and may not be reliable. It was a small, early-stage mechanistic study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BU School of Medicine Evans 748

    Boston, Massachusetts, 02118, United States